Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study size is 100 patients in 2 arms 50 patients in nilotinib ttt 50 patients in imatinib ttt
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic phase CML treated by nilotinib | Active Comparator | Newly diagnosed |
|
| Chronic phase CML treated by imatinib | Active Comparator | Newly diagnosed |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nilotinib 150 MG [Tasigna] | Drug | Nilotinib vs imatinib in patients with newly diagnosed CML-CP |
|
| Measure | Description | Time Frame |
|---|---|---|
| Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Overall survival rate in years | Overall survival rate in years | 3 years cutoff |
| Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Cholesterol level in mg | cholesterol level in mg | 3 years cutoff |
| Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Heart state by assessment by ECG | heart state by assessment by ECG | 3 years cutoff |
| Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Free survival rate in years | free survival rate in years | 3 years cutoff |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C498826 | nilotinib |
| D000068877 | Imatinib Mesylate |
| ID | Term |
|---|---|
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Imatinib 400mg | Drug | Nilotinib vs imatinib in patients with newly diagnosed CML-CP |
|
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |